Cargando…

Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer

BACKGROUND: The human epidermal growth factor receptor 2 (HER2) and p53 pathways may be involved in chemotherapy sensitivity and/or resistance. We explore the value of HER2 and p53 status to foretell docetaxel sensitivity in advanced breast cancer. METHODS: HER2 and p53 expression was analysed in 36...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camerini, Andrea, Donati, Sara, Viacava, Paolo, Siclari, Olimpia, Puccetti, Cheti, Tartarelli, Gianna, Valsuani, Chiara, De Luca, Filomena, Martini, Leonardo, Cavazzana, Andrea, Amoroso, Domenico
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080331/ https://www.ncbi.nlm.nih.gov/pubmed/21481270 http://dx.doi.org/10.1186/1756-9966-30-38

Ejemplares similares

Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report
por: Valsuani, Chiara, et al.
Publicado: (2009)

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
por: Camerini, Andrea, et al.
Publicado: (2015)

Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Canale, Maria Laura, et al.
Publicado: (2020)

Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial
por: Camerini, Andrea, et al.
Publicado: (2022)

Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis
por: Vinod, B S, et al.
Publicado: (2015)

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
por: Lv, Zhi-Dong, et al.
Publicado: (2022)

Grover disease associated with docetaxel chemotherapy
por: Afvari, Shawn, et al.
Publicado: (2022)

Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer
por: Cheng, Wei-Jie, et al.
Publicado: (2022)

High anthracycline cumulative dose without cardiac toxicity: A possible protective role of morphine
por: Canale, Maria Laura, et al.
Publicado: (2018)

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study
por: Tibaldi, C, et al.
Publicado: (2008)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
por: Rocca, Andrea, et al.
Publicado: (2021)

Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner
por: Moretti, Roberta M., et al.
Publicado: (2014)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

Clinical predictor of survival following docetaxel-based chemotherapy
por: LEE, HSIANG-YING, et al.
Publicado: (2014)

Nail Changes During Docetaxel Containing Combination Chemotherapy
por: Woo, In Sook, et al.
Publicado: (2004)

Trastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
por: Sonthalia, Sidharth, et al.
Publicado: (2017)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
por: Sugitani, Ikuko, et al.
Publicado: (2017)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Nail changes secondary to docetaxel chemotherapy : a case report
por: Ghafoor, Qamar, et al.
Publicado: (2008)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review
por: Engels, F K, et al.
Publicado: (2005)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
por: Mittal, Karuna, et al.
Publicado: (2017)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
por: Lin, Binwei, et al.
Publicado: (2023)

Palmar-plantar erythrodysesthesia secondary to docetaxel chemotherapy: a case report
por: Benghiat, Helen, et al.
Publicado: (2011)

Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report
por: Moloney, Thomas P, et al.
Publicado: (2014)

Generic docetaxel chemotherapy induced skin toxicities in breast cancer patient
por: Elalami, Iliass, et al.
Publicado: (2016)

Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy
por: Hua, Haiying, et al.
Publicado: (2017)

Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
por: Liu, Yan-cui, et al.
Publicado: (2019)

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies
por: Tuzi, Alessandro, et al.
Publicado: (2013)

HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination
por: Tiezzi, Daniel G, et al.
Publicado: (2007)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel
por: Joung, Jae Young, et al.
Publicado: (2008)

Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies
por: Koopaei, Mona Noori, et al.
Publicado: (2011)

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
por: Krishnan, Sreenath M., et al.
Publicado: (2021)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_240ahqos87fhma4mgss6bf2dc0